The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

JBM629

Forum Replies Created

Viewing 0 reply threads
  • Replies
      JBM629
      Participant
        I’m so happy for you! Thank you for sharing your story with me today. I’m trying so hard to stay positive and not let fear take over my life. Some days this still feels like a nightmare to me, and I can’t believe it’s happening. Encouragement and support from people like you are making a huge difference. I’m very grateful that I found this site and that people are willing to reach out. Your story has inspired me!!
        JBM629
        Participant
          Thank you!! I had Opdivo – 2 infusions, January and February – when I was Stage 3. I became exhausted. Diagnosis was liver toxicity. No immunotherapy after that until last week when I got infusion #1 of Yervoy! So far, so good. I’m putting Luke 1:37 on my bathroom mirror.
      Viewing 0 reply threads
      About the MRF Patient Forum

      The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

      The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

      Popular Topics